Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma

NCT00310518 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: ARQ 501

Sponsor

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)